Concure Oncology has raised $2.5 million in new capital for breast cancer treatment that makes use of radioactive seeds to forestall tumors from rising.
With the brand new funding, introduced final week, the Mercer Island-based startup has now secured greater than $12 million with the latest contribution coming from practically 25 traders, together with Chris Ackerley, managing director at Ackerley Companions, and Jeff Wright, chair of the Area Needle’s board.
This new spherical of funding goals to double the corporate’s discipline gross sales group and concentrate on coaching new clinicians throughout the nation in making its Breast Microseed Treatment accessible for ladies with early-stage breast cancer.
“This new financing marks an thrilling inflection level for the staff at Concure Oncology in addition to the sufferers that we deal with, now and shifting ahead,” stated Kevin Kelley, chief monetary officer of Concure Oncology, in a news release. “Mixed with the staff of scientific consultants that we’ve introduced on within the final 12 months and up to date main shifts in treatment and remedy, ladies dealing with breast cancer now ought to have a way more optimistic path ahead.”
The treatment works like this:
The Breast Microseed treatment first grew to become accessible within the U.S. on the Swedish Cancer Institute in 2016. Former CFO Kevin Kelley took over Concure Oncology early in 2018, according to his LinkedIn. Kelley co-founded the corporate in 2014 with former CEO Sandra Roem and Dr. Ralph Pascualy, a former doctor and government at Swedish Hospital in Seattle. The corporate has 12 full-time workers.